Global G-Protein Coupled Receptors (GPCRs) Industry

News provided by

Aug 13, 2012, 06:10 ET

NEW YORK, Aug. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global G-Protein Coupled Receptors (GPCRs) Industry

http://www.reportlinker.com/p0197194/Global-G-Protein-Coupled-Receptors-GPCRs-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_

This report analyzes the Global market for G-Protein Coupled Receptors (GPCRs) in US$ Billion. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 43 companies including 7TM Pharma A/S, Actelion Pharmaceuticals Ltd., Acure Pharma AB, Anchor Therapeutics, Arena Pharmaceuticals, Inc., Addex Pharmaceuticals, Acadia Pharmaceuticals Inc., Cara Therapeutics, Inc., DiscoveRx Corporation, Dimerix Bioscience Pty Ltd., Domain Therapeutics, Euroscreen SA, and Trevena, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Quick Primer II-1

Why GPCRs Are Important? II-1

Illustrative Examples of Currently Available Pharmaceutical

Drugs Targeting GPCRs II-1

Untapped Pharmacological Potential of GPCRs Ignites Interest II-2

Popular Types of GPCRs of Therapeutic Interest Currently

Being Studied Include: II-3

Current Knowledge of GPCR Crystal Structures Just the Tip of

the Iceberg II-3

NMR Spectroscopy: An Invaluable Tool to Study GPCR Structures II-4

Orphan GPCRs: A Promising Area for Drug Discovery II-4

Developments in Screening Technology for GPCRs II-5

Cell Membrane Assays for GPCR Quantitative Analysis II-5

What's in for the Pharmaceutical Industry? II-5

Challenges Aplenty in the GPCR Space II-6

Addressing Orphan GPCRs II-6

Lack of Structural Information II-6

Identification and Classification of Allosteric Sites II-6

2. G-PROTEIN COUPLED RECEPTORS (GPCR) - A CONCEPTUAL OVERVIEW II-7GPCR: Gateways to Cell II-7Classification of GPCRs II-7Table 1: List of Identified Known and Orphan (Non-Sensory)GPCRs in Human Genome (includes corresponding Graph/Chart) II-8Orphan GPCRs and Deorphanization II-8List of oGPCR-Ligand Pairings Identified By Using ReversePharmacology Approach II-9Structural Information II-9Rhodopsin: A Well Studied GPCR II-10Crystal Structure of Human Beta-2 Adrenergic GPCR II-10Structure of Human A2A Adenosine Receptor II-10Significance of GPCR Crystal Structures II-11GPCR Signaling Pathways II-11Physiological Roles Performed by GPCRs II-11Visual Sense II-11Cell-density Sensing II-11Regulation of mood and behavior II-11Smelling Sense II-12Regulating Immune-System Inflammation and Activity II-12Automatic Transmission of Nervous System II-12Receptor - Ligand Interaction II-12Types of Ligands II-12Therapeutic Potential of GPCRs II-12List of Major Disease States and Associated Known GPCRs II-13Allosteric Modulators and Implication of Allostery in DrugDiscovery II-13Advantages of Allosteric Modulators II-13Dimerisation and Role of Dimers in Drug Discovery II-14Oligomerisation and Role of Oligomers in Drug Discovery II-14Functional Selectivity II-14Existing Drug Candidates in GPCR Space II-15List of Existing GPCR-Based Drugs Available In Market AlongWith Their Target Receptor and Indication II-15Pipeline GPCR Drug Candidates II-15Ion Channels II-16Approaches to Drug Discovery in GPCR Space II-16Structure-Based Drug Discovery II-16Ligand-Based Drug Discovery II-16Target-Based Drug Discovery II-16GPCR Screening and Targeting Technologies II-16Cell-Based Screening Assays II-17Virtual Screening II-18Fragment screening II-18

3. RECENT INDUSTRY ACTIVITY II-19

Domain Therapeutics Enters into an Agreement with Merck Serono II-19

Anchor Therapeutics Makes a Breakthrough in GPCR Collaboration II-19

Receptos Collaborates with Lilly GPCR target II-19

Sanofi-aventis Enters into Licensing Agreement with Metabolex II-20

Neurocrine and Boehringer Ingelheim Join Hands to Develop

GPR119 Agonists II-20

Affitech Enters into Research Collaboration with NTS Plus II-20

Takeda Cambridge Inks an Agreement to Utilize Dimerix' GPCR-

HIT Platform II-21

PerkinElmer Unveils New Detection Kit for Profiling and

Screeing GPCRs II-21

Omeros Completes Acquisition of GPCR Assay Technology from

Patobios II-22

DiscoveRx Corporation Takes Over KINOMEscan™ II-22

Roche and ATCC Collaborate on Real-Time Endogenous GPCR

Function Research II-22

Millipore Launches Luminescent GPCR Reporter Frozen Cells II-22

Ascent Therapeutics re-christened as Anchor Therapeutics II-22

Affitech Sells Cancer Vaccine Project to Focus on GPCR Research II-23

Medarex Releases Pre-clinical Data for MDX-1338 II-23

Compugen Declares Positive Therapeutic Effects of CGEN-25009 II-23

Addex Releases Clinical Data for ADX10059 II-23

Arana Receives Patent Approval for PMX53 and Related GPCR

Compounds II-24

Epix Pharmaceuticals Receives Patent Approval for PRX-03140

and Related Compounds II-24

Odyssey Thera Receives Patent Approval for Fluorescence-Based

Assays II-24

Cisbio Bioassays Introduces Cellul'erk Assay II-24

DiscoveRx Introduces Products and Services to Assays and

Reagents Portfolio II-25

PerkinElmer Introduces Novel Ion Channel and GPCR Cell Lines II-25

Millipore Launches New AllostericProfilerTM Service II-25

Ligand Pharmaceuticals and Trevena Enter into Agreement II-25

ChanTest Takes Over ACS II-26

PerkinElmer Enters into Collaboration with Sangmyung University II-26

Debiopharm Group Inks Exclusive Agreement with MSM Protein

Technologies II-26

GVK Biosciences and University of Tokyo Sign Agreement II-26

MSM Protein Technologies Enters into Alliance with Merck Serono II-27

Xenome Enters into Agreement with Axxam II-27

DiscoveRx and GlaxoSmithKline Inks Global Agreement II-27

Sygnature Enters into Contract Chemistry Agreement with

Heptares Therapeutics II-27

Enzo Life Sciences Enters into Partnership with BioTek

Instruments II-28

Heptares Therapeutics Enters into Agreement with Novartis

Option Fund II-28

CellAura Enters into Partnership with Cisbio Bioassays II-28

Euroscreen and Novartis Ink Research Collaboration Agreement II-28

Evotec Enters into Co-marketing Agreement with DiscoveRx II-29

Jubilant Biosys Inks Co-marketing Agreement with DiscoveRx II-29

Faust Pharmaceuticals Changes Name to Domain Therapeutics II-29

GSK, MRCT and DiscoveRx Collaborate for Deorphanization of GPCRs II-29

DiscoveRx Inks Agreement with BioFocus II-30

Actelion's S1P1 Receptor Agonist to Enter into Phase II

Clinical Trial II-30

AnaSpec Introduces Two Isoform Specific Antibodies II-30

Millipore Introduces MultiScreen®HTS+ Filter Plates II-30

Faust & Takeda Enter into Research Agreement II-31

Caliper Life Sciences Collaborates with DiscoveRx II-31

Compugen Inks Agreement with Merck Serono II-31

BioFocus and Amgen Extend Drug Discovery Agreement II-31

DiscoveRx Selects Cosmo Bio to Distribute GPCR Profiling

Service across Japan II-31

Euroscreen Extends Agreement with Cephalon II-32

BioFocus DPI Introduces Novel Version of GPCR SARfari II-32

PerkinElmer Takes Over Euroscreen Products II-32

4. FOCUS ON SELECT GLOBAL PLAYERS II-337TM Pharma A/S (Denmark) II-33Actelion Pharmaceuticals Ltd. (Switzerland) II-33Acure Pharma AB (Sweden) II-33Anchor Therapeutics (USA) II-34Arena Pharmaceuticals, Inc. (US) II-34Addex Pharmaceuticals (Switzerland) II-34Acadia Pharmaceuticals Inc., (USA) II-35Cara Therapeutics, Inc. (USA) II-36DiscoveRx Corporation (USA) II-36Dimerix Bioscience Pty Ltd (Australia) II-36Domain Therapeutics (France) II-37Euroscreen SA (Belgium) II-37Trevena, Inc. (USA) II-37

5. GLOBAL MARKET PERSPECTIVE II-38

Table 2: World Recent Past, Current & Future Market Analysis

for G-Protein Coupled Receptors (GPCRs) Targeting Drugs

Analyzed with Annual Sales Figures in US$ Billion for Years

2009 through 2017 (includes corresponding Graph/Chart) II-38

Table 3: World Historic Review for G-Protein Coupled Receptors(GPCRs) Targeting Drugs Analyzed with Annual Sales Figures inUS$ Billion for Years 2003 through 2008 (includescorresponding Graph/Chart) II-39III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 43

------------------------------------------Region/Country Players------------------------------------------The United States 24Europe 15France 2Germany 1The United Kingdom 3Italy 1Rest of Europe 8Asia-Pacific (Excluding Japan) 3Middle East 1------------------------------------------

To order this report:In Vitro Diagnostic Industry: Global G-Protein Coupled Receptors (GPCRs) Industry

Market Research Report

Check our

Industry Analysis and Insights

Contact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker